natgillin/translations-raw huggingface dataset:
• in patients with Glanzmann's thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available. 
• pri bolnikih z Glanzmannovo trombastenijo s trenutno ali preteklo refraktarnostjo proti transfuzijam trombocitov, ali če trombociti niso takoj na voljo.
If you do not use it immediately after mixing, you should store the vial with the syringe still attached in a refrigerator at 2°C to 8°C for no longer than 24 hours. 
Če ga ne uporabite takoj, morate vialo s še vedno nameščeno brizgo shraniti v hladilniku pri temperaturi od 2 °C do 8 °C, vendar ne več kot 24 ur.
Subjects were stratified according to sex and ethnic group and dosed with 40, 80 and 160 µg rFVIIa per kg body weight (3 doses each) and/or placebo. 
Dobili so 40, 80 in 160 µg rFVIIa na kilogram telesne mase (3 odmerke vsakega) in/ali placebo.
Use the reconstituted NovoSeven at once to avoid infections. 
Pripravljeno zdravilo NovoSeven uporabite takoj, da boste preprečili okužbe.
If a larger dose is needed, repeat the procedure with additional vials, pre-filled syringes and vial adapters. 
Če je potreben večji odmerek, ponovite postopek z dodatnimi vialami, napolnjenimi injekcijskimi brizgami in nastavki za vialo.
• in patients with congenital haemophilia who are expected to have a high anamnestic response to factor VIII or factor IX administration 
• pri bolnikih s prirojeno hemofilijo, pri katerih je pričakovan visok anamnestičen odziv na uporabo faktorja VIII ali faktorja IX,
Clinical trials conducted in 484 patients (including 4297 treatment episodes) with haemophilia A and B, acquired haemophilia, factor VII deficiency or Glanzmann's thrombasthenia have shown that adverse drug reactions are common (≥ 1/100 to < 1/10). 
V kliničnih preskušanjih pri 484 bolnikih (4.297 epizod zdravljenja) s hemofilijo A in B, pridobljeno hemofilijo, pomanjkanjem faktorja VII ali Glanzmannovo trombastenijo so se neželeni učinki pojavljali pogosto (≥ 1/100 do < 1/10).
If you inject too much NovoSeven, get medical advice at once. 
Če injicirate večji odmerek zdravila NovoSeven, kot bi smeli Če injicirate preveč zdravila NovoSeven, nemudoma poiščite zdravniški nasvet.
The most frequent adverse drug reactions are pyrexia and rash (uncommon: > 1/1,000 to < 1/100), and the most serious adverse drug reactions are thromboembolic events. 
Najpogosteje se pojavljajta neželena učinka pireksija in izpuščaj (občasno: ≥ 1/1.000 do < 1/100), najresnejši neželeni učinki pa so trombembolični dogodki.
Pharmacokinetics of NovoSeven in patients with Glanzmann's thrombasthenia have not been investigated, but are expected to be similar to the pharmacokinetics in haemophilia A and B patients. 
Farmakokinetika zdravila NovoSeven pri bolnikih z Glanzmannovo trombastenijo ni raziskana, vendar je mogoče pričakovati, da je podobna farmakokinetiki pri bolnikih s hemofilijo A in B. 5.3 Predklinični podatki o varnosti
The powder for solution for injection contains: 1 mg/vial (corresponding to 50 KIU/vial), 2 mg/vial (corresponding to 100 KIU/vial), 5 mg/vial (corresponding to 250 KIU/vial) or 8 mg/vial (corresponding to 400 KIU/vial). 
Prašek za raztopino za injiciranje vsebuje: 1 mg/vialo (ustreza 50 k.i.e./vialo), 2 mg/vialo (ustreza 100 k.i.e./vialo), 5 mg/vialo (ustreza 250 k.i.e./vialo) ali 8 mg/vialo (ustreza 400 k.i.e./vialo).
peripheral ischaemia, peripheral arterial thrombosis and intestinal ischaemia) 
periferna ishemija, tromboza periferne arterije in ishemija črevesa)
The recommended dose for treatment of bleeding episodes and for the prevention of bleeding in patients undergoing surgery or invasive procedures is 90 µg (range 80 - 120 µg) per kg body weight at intervals of two hours (1.5 - 2.5 hours). 
Priporočeni odmerek za zdravljenje krvavitev in za preprečevanje krvavitev pri bolnikih, ki so prestali operacije ali invazivne postopke, je 90 µg (razpon od 80 do 120 µg) na kg telesne mase v dveurnih presledkih (od 1,5 do 2,5 ure).
Pharmacological doses of NovoSeven activate factor X directly on the surface of activated platelets, localized to the site of injury, independently of tissue factor. 
Farmakološki odmerki zdravila NovoSeven aktivirajo faktor X neposredno na površini aktiviranih trombocitov, ki se nahajajo na mestu poškodbe,
Using the FVII clotting assay, the pharmacokinetics of rFVIIa were investigated in 35 healthy Caucasian and Japanese subjects in a dose-escalation study. 
Farmakokinetiko rFVIIa so v študiji s povečevanjem odmerka raziskali pri 35 zdravih belskih in japonskih preiskovancih s koagulacijskim preizkusom z FVII.
In an observational registry (F7HAEM-3578) covering subjects with congenital FVII deficiency, the median dose for long term prophylaxis against bleeding in 22 paediatric patients (below 12 years of age) with Factor VII deficiency and a severe clinical phenotype was 30 µg/kg (range 17 µg/kg to 200 µg/kg; the dose most often used was 30 µg/kg in 10 patients) with a median dose frequency of 3 doses per week (range 1 to 7; the dose frequency most often reported was 3 per week in 13 patients). 
V opazovalnem registru (F7HAEM-3578), ki zajema osebe s prirojenim pomanjkanjem FVII, je bil mediani odmerek za dolgotrajno profilakso krvavitev pri 22 pediatričnih bolnikih (mlajših od 12 let) s pomanjkanjem faktorja VII in hudim kliničnim fenotipom 30 µg/kg (razpon: 17 µg/kg - 200 µg/kg; najpogosteje uporabljen je bil odmerek 30 µg/kg pri 10 bolnikih).
Each NovoSeven pack contains: 
Eno pakiranje zdravila NovoSeven vsebuje:
What you need to know before you use NovoSeven Do not use NovoSeven 
Kaj morate vedeti, preden boste uporabili zdravilo NovoSeven Ne uporabljajte zdravila NovoSeven,
If continued therapy is indicated, the dose interval can then be increased to 3 hours for 1 - 2 days. 
Če je indicirano nadaljnje zdravljenje, je mogoče odmerni interval nato 1 do 2 dneva podaljšati na 3 ure.
- Arterial thromboembolic events (myocardial infarction, cerebral infarction, cerebral ischaemia, cerebral artery occlusion, cerebrovascular accident, renal artery thrombosis, 
- arterijski trombembolični dogodki (miokardni infarkt, možganski infarkt, možganska ishemija, zapora možganske arterije,
• An in-line filter with a 5 micrometer pore size must be ensured for administration. 
• Za dajanje zdravila je treba zagotoviti, da je uporabljen linijski filter s 5-mikrometrsko velikostjo por.
It is recommended to use NovoSeven immediately after reconstitution, unless as described in section 
Priporočljivo je, da zdravilo NovoSeven uporabite takoj po pripravi, razen v primeru, opisanem v poglavju 6.3.
An initial dose of 90 µg per kg body weight is recommended and could be administered on the way to the hospital where the patient is usually treated. 
Priporočen je začetni odmerek 90 µg na kg telesne mase; aplicirati ga je mogoče na poti v bolnišnico,
• If you are prone to disseminated intravascular coagulation (DIC, a condition where blood clots develop throughout the blood stream) you must be carefully monitored. 
• če ste nagnjeni k diseminirani intravaskularni koagulaciji (DIK, stanje, pri katerem povsod v krvnem obtoku nastajajo krvni strdki).
Single dose pharmacokinetics of rFVIIa, 15 and 30 μg per kg body weight, showed no significant difference between the two doses used with regard to dose-independent parameters: Volume of distribution at steady state (280 - 290 ml/kg), half-life (2.82 - 3.11 h), total body clearance (70.8 - 79.1 ml/h×kg) and mean residence time (3.75 - 3.80 h). 
Farmakokinetika posamičnih odmerkov rFVIIa 15 in 30 µg na kg telesne mase se med odmerkoma ni značilno razlikovala po parametrih, neodvisnih od odmerka: volumnu porazdelitve v stanju dinamičnega ravnovesja (280-290 ml/kg), razpolovnem času (2,82-3,11 ure), skupnem telesnem očistku (70,8-79,1 ml/h×kg) in povprečnem času zadrževanja (3,75-3,80 ure).
Safely dispose of the syringe, vials, any unused product and other waste materials as instructed by your healthcare professional. 
Varno zavrzite brizgo, obe viali, morebitno neuporabljeno zdravilo in ostali odpadni material, tako kot vas je o tem poučilo vaše zdravstveno osebje.
Healthy subjects 
Zdravi preiskovanci
This results in the conversion of prothrombin into large amounts of thrombin independently of tissue factor. 
Posledica je pretvorba protrombina v veliko količino trombina,
• If you have Factor VII deficiency 
Če imate pomanjkanje faktorja VII:
There are no studies on the effect of NovoSeven on the ability to drive and use machines. 
Študij o vplivu zdravila NovoSeven na sposobnost upravljanja vozil in strojev niso izvedli.
Do not use the reconstituted solution if you notice particles in it or if it is discoloured. 
Pripravljene raztopine ne uporabite, če se v njej pojavijo delci ali če opazite, da je obarvana.
It is recommended to use NovoSeven immediately after reconstitution. 
Zdravilo NovoSeven je priporočljivo uporabiti takoj po pripravi.
Instructions on how to use NovoSeven READ THESE INSTRUCTIONS CAREFULLY BEFORE USING NOVOSEVEN 
Navodila za uporabo zdravila NovoSeven PRED UPORABO ZDRAVILA NOVOSEVEN NATANČNO PREBERITE TA NAVODILA
There is no clinical experience with administration of a single dose of 270 µg per kg body weight in elderly patients. 
Pri starejših bolnikih ni kliničnih izkušenj z uporabo posamičnega odmerka 270 µg na kilogram telesne mase.
The usual dose is 90 micrograms (range is 80 to 120 micrograms) for every 1 kilogram you weigh, for each injection. 
Običajni odmerek za vsako injekcijo je 90 mikrogramov (razpon od 80 do 120 mikrogramov) na vsak kilogram telesne mase.
Remove the protective paper from the vial adapter without taking it out of the protective cap. 
Odstranite zaščitni papir z nastavka za vialo, brez da bi ga vzeli iz zaščitnega pokrovčka.
Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. 
Napolnjena injekcijska brizga: telo iz stekla tipa I s polipropilensko vzvratno zaporo in batom iz bromobutilne gume.
The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or the surgery being performed. 
Trajanje zdravljenja in interval med injekcijami se razlikuje glede na to, kako huda je krvavitev, invazivni postopek ali operacija.
Take care not to touch the end of the transfer needle. 
Pazite, da se ne boste dotaknili konice igle.
• If you were born with haemophilia and do not respond normally to factors VIII or IX treatment 
• prirojeno hemofilijo in se ne odzivajo normalno na zdravljenje s faktorjem VIII ali IX,
• Lightly squeeze the protective cap with your thumb and index finger as shown. 
• S palcem in kazalcem rahlo stisnite zaščitni pokrovček, kot je prikazano.
Administration through a needleless connector may require withdrawal of the reconstituted solution into a standard 10 ml sterile luer-lock plastic syringe. 
Za aplikacijo zdravila skozi brezigelne konektorje bo morda potrebno izvleči pripravljeno raztopino v standardno 10-ml sterilno plastično brizgo, ki ima nastavek luer.
Signs may include skin rashes, itching, flushing and hives; wheezing or difficulty breathing; feeling faint or dizzy; and severe swelling of the lips or throat, or at the injection site. 
Med znaki so lahko izpuščaj na koži, srbečica, vročinski oblivi in koprivnica, piskajoče ali težko dihanje, omotica ali omedlevica in huda oteklost ustnic ali žrela ali oteklost na mestu injiciranja.
• If you have Glanzmann's thrombasthenia (a bleeding disorder) and your condition cannot be treated effectively with platelet transfusion, or if platelets are not readily available. 
• Glanzmannovo trombastenijo (motnjo strjevanja krvi), ki je ni mogoče učinkovito zdraviti s transfuzijo trombocitov, ali če trombociti niso takoj na voljo.
As recombinant coagulation factor VIIa NovoSeven may contain trace amounts of mouse IgG, bovine IgG and other residual culture proteins (hamster and bovine serum proteins), the remote possibility exists that patients treated with the product may develop hypersensitivity to these proteins. 
IgG in drugih rezidualnih beljakovin kulture (hrčkove in goveje serumske beljakovine), zato obstaja pri bolnikih, ki dobivajo to zdravilo, neznatna možnost za pojav preobčutljivosti na te beljakovine.
Following the initial dose of NovoSeven further injections may be given if required. 
Če je potrebno, je mogoče po začetnem odmerku zdravila NovoSeven dati še dodatne injekcije.
Table 1 lists adverse reactions reported during clinical trials and from spontaneous (post-marketing) reports. 
V preglednici 1 je prikazan seznam neželenih učinkov, ki so bili ugotovljeni v kliničnih preskušanjih in tistih, ki so bili spontano poročani po začetku trženja.
The NovoSeven powder must be reconstituted with its solvent and injected into a vein. 
Prašek NovoSeven je treba zmešati s topilom in injicirati v veno.
If you cannot use it immediately, after it has been mixed, you should store it in the vial with the vial adapter and syringe still attached in a refrigerator at 2°C to 8°C for no longer than 24 hours. 
Če ga ne morete uporabiti takoj po pripravi, ga morate shraniti v viali (nastavek za vialo in brizga morata ostati nameščena) v hladilniku pri temperaturi od 2 do 8 °C, vendar ne več kot 24 ur.
Hydrochloric acid (for pH-adjustment) Sodium hydroxide (for pH-adjustment) Water for injections 
Topilo histidin klorovodikova kislina (za uravnavanje pH) natrijev hidroksid (za uravnavanje pH) voda za injekcije
Your doctor may recommend a single dose of 270 micrograms for every 1 kilogram you weigh. 
Zdravnik vam lahko svetuje posamičen odmerek 270 mikrogramov na vsak kilogram telesne mase.
Do not touch the syringe tip under the syringe cap. 
Ne dotikajte se konice injekcijske brizge pod pokrovčkom injekcijske brizge.
Only after consultation with the haemophilia treatment centre can continued home treatment be considered. 
Nadaljnje zdravljenje na domu pride v poštev šele po posvetu s centrom za zdravljenje hemofilije.
Table 1 Adverse reactions from clinical trials and spontaneous (post-marketing) reports 
Preglednica 1 Neželeni učinki iz kliničnih preskušanj in neželeni učinki, spontano poročani po začetku trženja
There is no requirement for monitoring of NovoSeven therapy. 
Zdravljenja z zdravilom NovoSeven ni treba nadzirati.
Wipe the rubber stopper on the vial with a sterile alcohol swab and allow it to dry for a few seconds before use. 
Gumijasti zamašek viale obrišite s sterilnim alkoholnim zložencem in pustite nekaj sekund, da se posuši, preden vialo uporabite.
For instructions on reconstitution of the medicinal product before administration, see section 6.6. 
Način uporabe Za navodila o pripravi raztopine pred uporabo glejte poglavje 6.6.
• 1 vial with white powder for solution for injection 
• 1 vialo z belim praškom za raztopino za injiciranje,
Data on a limited number of exposed pregnancies within approved indications indicate no adverse effects of rFVIIa on pregnancy or on the health of the foetus/new-born child. To date, no other relevant epidemiological data are available. 
Podatki, zbrani pri omejenem številu nosečnic, ki so bile izpostavljene zdravilu pri odobrenih indikacijah, ne kažejo neželenih učinkov rFVIIa na nosečnost ali zdravje ploda/novorojenca.
In vial 
V viali
Injecting NovoSeven with pre-filled syringe via needleless connectors for intravenous (IV) catheters 
Injiciranje zdravila NovoSeven z napolnjeno injekcijsko brizgo in brezigelnimi konektorji za intravenske (i.v.)
Powder and solvent for solution for injection. 
prašek in topilo za raztopino za injiciranje
NovoSeven must not be mixed with infusion solutions or be given in a drip. 
Zdravila NovoSeven se ne sme mešati z raztopinami za infundiranje ali dajati v kapalni infuziji.
The reconstituted solution has a pH of approximately 6.0. 
Pripravljena raztopina ima pH približno
Sodium chloride, calcium chloride dihydrate, glycylglycine, polysorbate 80, mannitol, sucrose, methionine, histidine, water for injections 
natrijev klorid, kalcijev klorid dihidrat, glicilglicin, polisorbat 80, manitol, saharoza, metionin, histidin in voda za injekcije.
• Store powder and solvent protected from light. 
• Prašek in topilo shranjujte zaščiteno pred svetlobo.
Check the solution for visible particles and discolouration. 
Preglejte, da raztopina ne vsebuje vidnih delcev in ni obarvana.
• Nausea (feeling sick) 
• siljenje na bruhanje (slabost v želodcu)
Signs may include difficulty in breathing, red and painful swelling in the leg and abdominal pain. 
Med znaki so lahko težko dihanje, pordela in boleča oteklost noge ter bolečine v trebuhu.
The ingredients in the solvent are histidine, hydrochloric acid, sodium hydroxide, water for injections. 
Topilo vsebuje histidin, klorovodikovo kislino, natrijev hidroksid in vodo za injekcije.
Each pack contains: 1 vial of powder 1 vial of solvent 
Vsako pakiranje vsebuje: 1 vialo s praškom, 1 vialo s topilom.
site, pulmonary embolism, thromboembolic events of the liver 
pljučna embolija, trombembolični dogodki v jetrih,
Haemophilia A and B with inhibitors 
Hemofilija A ali B z zaviralci
If you use a vial adapter, tip the syringe to remove it from the vial. 
Če uporabljate nastavek za vialo, zasučite brizgo, da ga boste odstranili z viale.
- Store powder and solvent protected from light. 
- Prašek in topilo shranjujte zaščiteno pred svetlobo.
• Take the vial, the vial adapter and the pre-filled syringe out of the carton. 
• Vzemite vialo, nastavek za vialo in napolnjeno injekcijsko brizgo iz škatle.
Store protected from light 
Shranjujte zaščiteno pred svetlobo.
• While holding the vial upside down, tap the syringe gently to let any air bubbles rise to the top. 
• Medtem ko držite vialo obrnjeno na glavo, previdno potrkajte po brizgi, da se bodo morebitni zračni mehurčki dvignili na vrh.
Stop pushing the plunger rod and let it move back on its own while the reconstituted solution fills the syringe. 
Nehajte potiskati nosilec bata in pustite, da se sam od sebe pomika nazaj, medtem ko pripravljena raztopina polni brizgo.
• Ensure that the plunger is pushed all the way in before turning the syringe upside down (it may have been pushed out by the pressure in the syringe). 
• Preden obrnete brizgo na glavo, poskrbite, da bo bat potisnjen do konca (morda ga je pritisk v brizgi nekoliko iztisnil).
• in patients with congenital haemophilia with inhibitors to coagulation factors VIII or 
• pri bolnikih s prirojeno hemofilijo z zaviralci koagulacijskih faktorjev VIII ali IX >
Safely dispose of the syringe, vials and any unused product. 
Varno zavrzite brizgo, obe viali in morebitno neuporabljeno zdravilo.
How to use NovoSeven 
Kako uporabljati zdravilo NovoSeven
Prepare the vial and the syringe 
Pripravite vialo in injekcijsko brizgo
It works by making the blood clot at the site of bleeding, when the body's own clotting factors are not working. 
Učinkuje tako, da v primeru, ko bolnikovi lastni faktorji strjevanja ne delujejo, naredi strdek na mestu krvavitve.
• NovoSeven is now ready for injection. 
• Zdravilo NovoSeven je zdaj pripravljeno za injiciranje.
Ensure that the plunger is pushed all the way in before turning the syringe upside down (it may have been pushed out by the pressure in the syringe). 
Preden obrnete brizgo na glavo, poskrbite, da bo bat potisnjen do konca (morda ga je pritisk v brizgi nekoliko iztisnil).
If you notice visible particles or discolouration, do not use it. Use a new package instead. 
Če opazite vidne delce ali obarvanost, je ne uporabite.
• Remove the syringe cap from the pre-filled syringe by bending it down until the perforation breaks. 
• Odstranite pokrovček injekcijske brizge z napolnjene injekcijske brizge, tako da ga upognete navzdol, dokler se perforacija ne prelomi.
The expiry date is printed after ‘EXP' on the outer carton, on the vial, on the vial adapter and on the pre-filled syringe. 
Datum izteka roka uporabnosti je natisnjen na škatli, viali, nastavku za vialo in na napolnjeni injekcijski brizgi poleg oznake “Uporabno do”.
Patients with acquired haemophilia 
Bolniki s pridobljeno hemofilijo
• Remove the plastic cap from the vial. 
• Odstranite plastični pokrovček z viale.
NovoSeven should be given as early as possible after the start of a bleeding episode. 
Zdravilo NovoSeven je treba dati čim prej po začetku krvavitve.
Overleaf: Instructions on how to use NovoSeven 
Na drugi strani lista: Navodila za uporabo zdravila NovoSeven
When NovoSeven is administered to patients outside approved indications, arterial thromboembolic events are common (≥ 1/100 to < 1/10). 
Trombembolični dogodki - arterijski in venski Če je zdravilo NovoSeven uporabljeno pri bolnikih zunaj odobrenih indikacij, so arterijski trombembolični dogodki pogosti (≥ 1/100 do < 1/10).
The duration of treatment and the interval between injections will vary with the severity of the haemorrhage, the invasive procedures or surgery being performed. 
Trajanje zdravljenja in presledek med injekcijami se razlikujeta glede na izrazitost krvavitve oz. potrebne invazivne postopke ali operacijo.
Push the plunger rod slowly until all air bubbles are gone. 
Nosilec bata počasi potiskajte, dokler vsi zračni mehurčki ne izginejo.
The risk of a potential interaction between NovoSeven and coagulation factor concentrates is unknown. 
4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij Tveganje za možne interakcije med zdravilom NovoSeven in koncentrati koagulacijskih faktorjev ni znano.
Solvent: clear colourless solution. 
Topilo: bistra, brezbarvna raztopina.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton text 
PODATKI NA ZUNANJI OVOJNINI Besedilo na škatli
Plastic cap Rubber stopper 
Pregled plastični pokrovček gumijasti zamašek
For single dose injection 
Za injiciranje v enkratnem odmerku.
Do not use the equipment without proper training from your doctor or nurse. 
Ne uporabljajte opreme, dokler vas vaš zdravnik ali medicinska sestra tega ne naučita ustrezno.
If continued therapy is needed, the dose interval can be increased successively once effective haemostasis is achieved to every 4, 6, 8 or 12 hours for as long as treatment is judged as being indicated. 
Če je treba zdravljenje nadaljevati, je mogoče potem, ko je dosežena učinkovita hemostaza, odmerni interval postopoma podaljševati na 4, 6, 8 ali 12 ur, dokler je zdravljenje indicirano.
Push the plunger rod gently to inject a little air into the vial. 
Previdno potisnite bat, da boste v vialo injicirali malo zraka.
The solvent of NovoSeven is provided in either a vial or in a pre-filled syringe. 
Topilo za zdravilo NovoSeven je na voljo v viali ali v napolnjeni injekcijski brizgi.
Keep the plunger rod pressed down and swirl the vial gently until all the powder is dissolved. 
Nosilec bata držite pritisnjen dol in previdno vrtite vialo, dokler se ves prašek ne raztopi.
Once haemostasis has been achieved, the dose interval can be increased successively to every 4, 6, 8 or 12 hours for as long as treatment is judged to be indicated. 
Ko je dosežena hemostaza, je mogoče odmerni interval postopno podaljševati na vsake 4, 6, 8 ali 12 ur za toliko časa, kot je indicirano zdravljenje.
NovoSeven reconstituted product is a clear, colourless solution. 
Pripravljena raztopina NovoSeven je bistra in brezbarvna.
The solvent is a histidine solution. 
Topilo je raztopina s histidinom.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve pridobitve: 23. februar 1996
Thereafter, the dose interval can be increased successively to every 4, 6, 8 or 12 hours for as long as treatment is judged as being indicated. 
Potem je mogoče odmerni interval postopoma podaljševati na 4, 6, 8 ali 12 ur, dokler je zdravljenje indicirano.
NovoSeven is now ready for injection. 
NovoSeven je tako pripravljen za injiciranje.
- 1 vial (12 ml) with white powder for solution for injection - 1 pre-filled syringe (10 ml) with solvent for reconstitution - 1 plunger rod - 1 vial adapter, with an integrated particle filter with a pore size of 25 micrometer. 
- 1 vialo (12 ml) z belim praškom za raztopino za injiciranje, - 1 napolnjeno injekcijsko brizgo (10 ml) s topilom za pripravo raztopine, - 1 nosilec bata, - 1 nastavek za vialo z integriranim filtrom za delce z velikostjo por 25 mikrometrov.
Remove the empty solvent vial. 
Odstranite prazno vialo s topilom.